INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
Subscribe
INDUSTRIALISATION
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
CONTRIBUTE
MEDIA PACK
SEARCH
SEARCH
advanced search
NASAL
NASAL
DE-RISKING DEVICE SELECTION – WHY CHOOSE UNISPRAY FOR NALOXONE RESCUE APPLICATIONS
Elsie Thomas explains why UniSpray is a robust nasal platform for generic naloxone, based on an evidence-driven approach that combines usability studies, threshold analyses and interchangeability assessments, and how it ensures safe and reliable performance, intuitive use, and regulatory acceptability in real-world opioid overdose rescue situations.
NASAL
REFRAMING THE ROLE OF NASAL SPRAYS IN AN INCREASINGLY PATIENT-CENTRIC DRUG DELIVERY LANDSCAPE
Eric Kaneps looks at the reality of nasal drug delivery for liquid formulations and considers how advances not only open new opportunities but can also be seen in the context of a groundswell of momentum around non-invasive, patient-centric delivery. Mr Kaneps reflects on how this shift in dynamics, coupled with a shift in mindset, is opening the door for pharmaceutical companies to expand their drug delivery options and fully optimise the development pathway for their molecule.
NASAL
Dr Alan Watts
Catalent Pharma Solutions
EXPANDING HORIZONS IN LIQUID NASAL DRUG DEVELOPMENT
Dr Alan Watts and David Wilcox examine the current product designs in the nasal market landscape and outline key technical and regulatory considerations for liquid nasal drug products.
EXPERT VIEW
Dr Matthew Owen
INTRANASAL DRUG DELIVERY: FORMULATION, DEVICE DESIGN & CHARACTERISATION STRATEGIES
Dr Matthew Owen reviews the formulation and device challenges, designs and considerations that are shaping the nasal delivery market.
NASAL
SGD Pharma
MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION
SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.
INTERVIEW
Christophe Pierre
Aptar Pharma
Interview: Aptar Pharma Expansion With New R&D Center
In this interview, Christophe Pierre introduces Aptar Pharma’s new R&D Center in France, and outlines how the new facility will assist the development of smarter, more integrated drug delivery solutions, facilitating progression from concept to full-scale industrialisation across multiple therapeutic fields.
EXPERT VIEW
Mark Parry
RESPIRATORY MUCOSAL VACCINATION: HOW COULD WE DELIVER ANOTHER GLOBAL VACCINATION RESPONSE WITH CURRENT DEVICE TECHNOLOGIES?
Mark Parry discusses the potential needs and opportunities for respiratory drug delivery devices in the context of a hypothetical global vaccination strategy, considering a variety of factors and how different respiratory device approaches could perform.
EXPERT VIEW
Dr Yannick Baschung
STRESS-TESTING INHALED MEDICINE SO PATIENTS CAN BREATHE EASIER
Dr Yannick Baschung discusses the benefits and challenges of orally inhaled and nasal drug products and examines how drug developers can stress test their products to improve regulatory success and patient safety, as well as how partnering with an expert CRO can provide an efficient way of performing critical characterisation testing.
EXPERT VIEW
Jamie Clayton
DISSOLUTION TESTING FOR ORALLY INHALED PRODUCTS: CONFRONTING THE CHALLENGES, REALISING THE POTENTIAL
As dissolution testing rises up the agenda for orally inhaled product developers, Jamie Clayton explores drivers behind its adoption and key considerations for developing a robust and relevant method.
EXPERT VIEW
Dr Peter Harley
HOW CUTTING EDGE IN SILICO APPROACHES CAN REDUCE TIME AND RISK IN DEVELOPMENT OF INHALATION DEVICES
Dr Peter Harley, Mariam Al-Amari and Matt Jones explore how in silico approaches can transform pulmonary and nasal drug delivery device development, illustrating through case studies – spanning low-global-warming potential propellants, assembly robustness, device-user interaction, variability and capsule piercing dynamics – how simulation-led in silico approaches can improve understanding of device performance and identify risks early, reducing development costs and accelerating the path to more reliable, innovative and patient-friendly drug-device systems.
NASAL
Matthias Müller
Contexo
FAST-TO-MARKET DEVELOPMENT OF A NOVEL NASAL SPRAY WITH SIMULTANEOUS ENGINEERING
Matthias Müller details how a close collaboration between Contexo and a pharmaceutical manufacturer led to the rapid development of a novel nasal spray product, taking the project from prototyping to market within 14 months, shaving 10 months off the anticipated launch date.
RESPIRATORY
Ross Errington
Bespak
FACILITY SPOTLIGHT: UK-BASED CAPABILITIES IN INHALED AND NASAL DRUG-DEVICE PRODUCT DEVELOPMENT
Ross Errington introduces Bespak’s Holmes Chapel (UK) site, which is equipped to support device development programmes from early-stage formulation to large-scale manufacture.
RESPIRATORY
Dr Philippe Rogueda
Merxin Ltd
TRANSFORMING MENTAL HEALTHCARE: THE RISE OF INHALABLE PSYCHEDELICS?
Philippe Rogueda discusses how inhaled psychedelic therapies are emerging as a potential game-changer in mental health due to their fast onset and precise dosing, and how their potential has resulted in a growing pipeline of therapies, paving the way for a new era in mental healthcare.
NASAL
Sophie Conte
Nemera
NOSE-TO-BRAIN DELIVERY: PATIENT-CENTRIC DEVICE DEVELOPMENT AND PERFORMANCE TESTING
Sophie Conte and Alain Regard, describe Nemera’s journey in nose-to-brain device development, highlighting the evaluation tools, methods and usability testing developed in-house to steer innovative device design and engineering.
EXPERT VIEW
Eric Kaneps
MEETING THE DEMAND FOR PATIENT CENTRICITY WITH NASAL SPRAY REPOSITIONING
Eric Kaneps discusses key emerging drug delivery trends poised to help the pharmaceutical industry meet the growing demand for patient-centric solutions, with a particular focus on nasal drug delivery, as the nasal spray repositioning of existing drugs offers a range of benefits, including rapid onset of action, improved bioavailability and ease of administration for patients.
NASAL
Mark Ignaczak
Catalent Pharma Solutions
STRATEGIES FOR SELECTING THE RIGHT CDMO FOR NASAL DRUG DELIVERY
Mark Ignaczak explores the current nasal drug delivery landscape and outlines key considerations for choosing the right CDMO to ensure the success of nasal drug projects.
INDUSTRIALISATION
Lorenzo Vaccarella
Paragon Medical
FUTURE-PROOFING YOUR DRUG DELIVERY DEVICE: CONSIDERATIONS FOR EFFECTIVE DESIGN
Lorenzo Vaccarella highlights six critical areas to consider early in the drug delivery device development journey. He discusses how strategically investing time during the early stages of the design cycle and throughout development can ultimately save both time and cost down the road when the product is being manufactured and deployed into the market.
SUSTAINABILITY
Dr Marie-Christine Klein
URSATEC
TOWARDS A COMPREHENSIVE SUSTAINABILITY STRATEGY
Marie-Christine Klein and Christian Weyler, look at the evolution of the company’s sustainability strategy within its regulatory and economic framework – and what decarbonisation means for the pharmaceutical industry.
NASAL
Alain Regard
Nemera
ADDRESSING CNS THERAPIES THROUGH NOSE-TO-BRAIN PATHWAYS
Alain Regard, Raphaële Audibert and Audrey Chandra, discuss the advantages of nasal delivery and highlight the challenges of the nose-to-brain pathways.
NASAL
Shai Assia
Clexio Biosciences
HUMAN FACTORS IN THE ABSENCE OF A FAMILIAR MENTAL MODEL: CHALLENGES & OPPORTUNITIES IN DRUG SELF-ADMINISTRATION
Shai Assia explores the intricate challenge of designing drug-device combination products for self-administration by lay users without medical expertise, focusing on targeted nasal drug delivery devices.
INTERVIEW
Dr Julie Suman
Aptar Pharma
Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT
Julie Suman discusses nasal casts, their development, applications and significance for nasal drug product development.
RESPIRATORY
Gemma Budd
Aptar Pharma
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.
INTERVIEW
Dr Sandy Munro
Phillips Medisize
Interview with Sandy Munro, Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials.
RESPIRATORY
Mike Needham
Kindeva
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
Mike Needham takes a look at the history of, and progress in, inhalation technology and discusses what might lie ahead.
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
1
2
3
…
6
Next
Top
